<DOC>
	<DOCNO>NCT01790295</DOCNO>
	<brief_summary>The purpose study find give study drug Ruxolitinib ( INC424 ) prior combination chemotherapeutic drug ( Fludarabine Busulfan ) infuse another person 's hematopoietic stem cell ( bone marrow transplantation ) successful people advance primary myelofibrosis ( PMF ) , post-polycythemia vera myelofibrosis ( PPV-MF ) post-essential thrombocythemia myelofibrosis ( PET-MF ) , collectively know myelofibrosis ( MF ) . MF disorder bone marrow tissue develop abnormal site bone marrow undergoes fibrosis scarring . This study plan evaluate whether add drug Ruxolitinib aid reduce pre-transplant spleen size , improve physical performance level reduce adverse event ( side effect ) relate transplant . Ruxolitinib drug approve FDA treatment patient advance forms myelofibrosis . Using Ruxolitinib prior stem cell transplantation experimental .</brief_summary>
	<brief_title>Ruxolitinib Prior Transplant Patients With Myelofibrosis</brief_title>
	<detailed_description>A two- stage Simon Phase II study conduct two group patient : relate unrelated donor transplant . In donor transplant group , first stage design include 11 patient evaluate death graft failure 100 day post-transplant . In stratum , enroll additional patient ( 20 % ) stratum total take account exclusion due donor failure ( donor deem unsuitable stem cell donation due medical reason ) . Those patient toxicity relate Ruxolitinib able reach HCT due toxicity include estimation overall failure rate . Only patient exclude base donor related issue without regimen related complication exclude estimation failure rate . However , data patient report .</detailed_description>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Polycythemia</mesh_term>
	<mesh_term>Polycythemia Vera</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<criteria>Documented diagnosis primary myelofibrosis accord WHO criteria post PV myelofibrosis post ET myelofibrosis per IWGMRT criterion Age 1870 year Intermediate2/ highrisk disease per Dynamic IPSS ( DIPSS ) criterion OR Intermediate1 risk disease one follow additional unfavorable feature know impact survival adversely 1 . Red cell transfusion dependency 2 . Unfavorable Karyotype 3 . Platelet count &lt; 100 x 109/l Blasts PB BM ≤10 % prior study enrollment Availability suitable match relate ( 6/6 5/6 ) unrelated donor ( 10/10 9/10 antigen allele match ) . Able give inform write consent ECOG Performance status 02 . Life expectancy &gt; 3 month Off MFdirected therapy include investigational agent least 2 week prior study enrollment recover toxicities* Adequate organ function Adequate renal function creatinine &lt; 1.5 x IULN Adequate hepatic function AST/ALT &lt; 2.5 x IULN , Total Bilirubin &lt; 1.5 x IULN Adequate hematopoietic function Platelet ≥50 x 109/l ANC ≥1.0 x 109/l LVEF &gt; 40 % ( MUGA echocardiogram ) Normal per Institutional standard Adequate pulmonary function DLCO &gt; 50 % A patient stable dose Ruxolitinib receive ruxolitinib ≤6 month prior study entry consider potentially eligible study caveat evidence loss response ( &gt; 5cm increase spleen size nadir ) . Any previous JAK2 inhibitor treatment prior study enrollment , exception Ruxolitinib Hypersensitivity JAK inhibitor Clinical laboratory evidence cirrhosis Prior allogeneic transplant hematopoietic disorder &gt; 20 % blast PB BM prior HCT leukemic transformation ( &gt; 20 % blast PB BM time prior HCT ) Syngeneic donor Cord Blood transplant Active uncontrolled infection H/o another malignancy within 5years date HCT except h/o basal cell squamous cell carcinoma skin PV ET Known HIV positive Pregnancy time BMT Any concurrent illness investigator 's opinion put patient excessive risk treatment related toxicity Unable give inform consent Active infection hepatitis A , B C virus Subjects require therapy strong CYP3A4 inhibitor prior enrollment study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Myelofibrosis</keyword>
	<keyword>Stem cell transplant</keyword>
	<keyword>Ruxolitinib</keyword>
</DOC>